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384Low-Dose Total Body Irradiation and Fludarabine
Conditioning for HLA Class I-Mismatched Donor Stem
Cell Transplantation and Immunologic Recovery
in Patients with Hematologic Malignancies:
A Multicenter Trial
Hirohisa Nakamae,1 Barry E. Storer,1,2 Rainer Storb,1,2 Jan Storek,1,3
Thomas R. Chauncey,1,2,4 Michael A. Pulsipher,5 Finn B. Petersen,6 James C. Wade,7
Michael B. Maris,8 Benedetto Bruno,9 Jens Panse,10 Effie Petersdorf,1,2 Ann Woolfrey,1,2
David G. Maloney,1,2 Brenda M. Sandmaier1,2HLA-mismatched grafts are a viable alternative source for patients without HLA-matched donors receiving
ablative hematopoietic cell transplantation (HCT), although their use in reduced intensity conditioning
(RIC) or nonmyeloablative (NMA) conditioning HCT has been not well established. Here, we extended
HCT to recipients of HLA class I-mismatched grafts to investigate whether NMA conditioning can establish
stable donor engraftment. Fifty-nine patients were conditionedwith fludarabine (Flu) 90mg/m2 and 2Gy total
body irradiation (TBI), followed by immunosuppression with cyclosporine (CsA) 5.0 mg/kg twice a day and
mycophenolate mofetil (MMF) 15 mg/kg 3 times a day for transplantation of granulocyte colony-stimulating
factor (G-CSF)-mobilized peripheral blood stem cells (PBSCs) from related (n 5 5) or unrelated donors
(n5 54) with 1 antigen6 1 allele HLA class I mismatch or 2 HLA class I allele mismatches. Sustained donor
engraftment was observed in 95% of the evaluable patients. The incidence of grade II-IV acute and extensive
chronic graft-versus-host disease (aGVHD, cGVHD) was 69% and 41%, respectively. The cumulative proba-
bility of nonrelapse mortality (NRM) was 47% at 2 years. Two-year overall and progression-free survival (OS,
PFS) was 29% and 28%, respectively. NMA conditioning with Flu and low-dose TBI, followed by HCTusing
HLA class I-mismatched donors leads to successful engraftment and long-term survival; however, the high
incidence of aGVHD and NRM needs to be addressed by alternate GVHD prophylaxis regimens.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) from HLA-matched donors is a well- estab-
lished curative strategy for patients with hematopoietic
malignancies; however, only 20% to 30% of patients
needing HSCT have a genotypically matched sibling
donor. Although unrelated donor registries have
grown enormously, currently potential donors cannot
be identified for 20% of Caucasian recipients andmore
than 60% of African-American recipients. Moreover,
patients with rare haplotypes are unlikely to find
HLA-matched unrelated donors (MUDs) in a timely
fashion. There is a need for a suitable transplantation
procedure that can extend the application of HSCT
with reduced-intensity conditioning (RIC) or non-
myeloablative (NMA conditioning to patients who
have no readily available HLA-matched donor.
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related donors, have been explored to extend the donor
pool [1,2].
The use of HLA class I-mismatched unrelated do-
nors is associated with an increased risk of graft rejec-
tion in the myeloablative (MA) setting [3-5]. The
intensity of conditioning for HSCT is also associated
with successful engraftment. Thus, the increased risk
of graft rejection in the HLA-mismatched NMA set-
ting compared with the MA setting may result from
less-intensive conditioning. The degree of mismatch
that would lead to unacceptable levels of rejection in
recipients of NMA HSCT is not known.
Based on preclinical studies [6], we have success-
fully applied a NMA conditioning regimen involving
fludarabine (Flu) 90 mg/m2, 2 Gy of total body irradi-
ation (TBI), and postgrafting immunosuppression
with mycophenolate mofetil (MMF) and cyclosporine
(CsA) as conditioning for grafts from either HLA-
matched related or MUD in more than 1200 patients
ineligible for high-dose HSCT because of advanced
age or comorbidities [7-12]. In this multicenter phase
I/II trial, we extended NMA HSCT to include recipi-
ents of related or unrelated granulocyte colony-stimu-
lating factor (G-CSF)mobilized peripheral blood stem
cell (PBSC) grafts from donors who were mismatched
for 1 HLA-class I antigen with or without 1 allele-level
HLA-class I mismatches, or donors who were mis-
matched for 2HLA-class I alleles. In addition, we eval-
uated immune reconstitution after HSCT in a subset
of the unrelated recipients.PATIENTS, MATERIALS, AND METHODS
This phase I/II multicenter trial included 7 trans-
plant centers: Fred Hutchinson Cancer Research Cen-
ter (FHCRC), University of Utah, University of
Torino, Medical College of Wisconsin, LDS Hospi-
tal, Rocky Mountain Cancer Center, and Veterans Af-
fairs Puget Sound Health Care System, with FHCRC
acting as the coordinating center. The study protocol
was approved by the institutional review boards of
FHCRC and the collaborating performance sites.
Written informed consent was obtained from all pa-
tients.
Study Endpoints
The primary objective of this trial was to deter-
mine whether stable allogeneic engraftment from re-
lated and unrelated HLA-mismatched PBSC donors
could be safely established using the NMA Flu/2Gy
TBI conditioning regimen with or without escalating
doses of the anti-CD52 monoclonal antibody (mAb)
alemtuzumab in patients with hematologic malignan-
cies. Secondary objectives included evaluation of acute
and chronic graft-versus-host disease (aGVHD,cGVHD), infections, disease progression and relapse,
and immunologic reconstitution.
Eligibility Criteria
All of the 59 patients enrolled in this study were
ineligible for conventional HSCT and had disease ex-
pected to be stable for at least 100 days without further
chemotherapy. Forty-one patients were aged . 50
years; the 18 patients aged# 50 years met the eligibil-
ity criteria either because of previous HSCT (autolo-
gous, n 5 14; allogeneic, n 5 1), neurologic toxicity
(n5 1), fungal infection and a history of major toxicity
to chemotherapy (n 5 1), or pancytopenia for 3
months (n 5 1).
Histocompatibility testing for donor selection was
performed for all patients and donors, using methods
described previously [13-15]. HLA-A, -B, -C,
-DRB1, and -DQB1 alleles were typed prospectively
by oligonucleotide hybridization or DNA sequencing
methods [16]. Donor-recipient compatibility was fur-
ther tested by lymphocyte cross-match (recipient se-
rum vs donor T and B cells) before HSCT [17].
Related or unrelated donors were allowed if matched
for HLA-DRB1 and -DQB1 alleles, and mismatched
for a single antigen at HLA-A, -B, or -C, with or with-
out an additional single allele mismatch at HLA-A, -B,
or -C. Donors were excluded if the recipient was
homozygous at the mismatched locus, or if both mis-
matches were at the same locus (HLA-A, -B, or -C).
Patients were ineligible for the present study if
they were pregnant or breast-feeding, or had rapidly
progressive intermediate- or high-grade non-Hodgkin
lymphoma (NHL), circulating leukemic blasts in the
PB detected by standard pathology, central nervous
system involvement refractory to intrathecal chemo-
therapy, infection with the human immunodeficiency
virus (HIV), active bacterial or fungal infection unre-
sponsive to therapy, decompensated liver disease, cor-
rected pulmonary diffusion capacity\ 35%, cardiac
ejection fraction\ 35%, poorly controlled hyperten-
sion, or a Karnofsky performance score\ 50%.
Patient Characteristics
A total of 59 patients were enrolled between Feb-
ruary 2002, andOctober 2008 (Table 1). Classification
for risk of relapse, as described previously [18], found
16 patients with high-risk disease, 27 with standard-
risk disease, and 16 with low-risk disease. Disease sta-
tus at the time of HSCT included complete remission
(CR) in 29 patients, partial remission (PR) in 14, stable
disease (SD) in 4, and refractory or relapsed disease in
12. All patients with acute myelogenous leukemia
(AML), secondary AML from myelodysplastic syn-
drome (MDS/AML), or acute lymphoblastic leukemia
(ALL) were in CR at the time of HSCT. Four patients
received a planned tandem autologous transplant
Table 1. Patient and Disease Characteristics
Number of patients 59
Median age, years, n (range) 56 (13-72)
Males/females, n 44/15
Unrelated/related donor, n 54/5
Previous courses of chemotherapy,
n (range)
6 (2-19)
Previous transplantations
(autologous/allogeneic), n
26/1
Time to HCT, months, median
(range)
36 (5-205)
Dose of CD34+ G-CSF-mobilized
PBSCs, median (range)
7.0  106 cells /kg (2.1-37.7  106
cells/kg)
Dose of CD3+ G-CSF-mobilized
PBSCs, median (range)
2.6  106 cells /kg (0.3-6.6  108
cells/kg)
Diagnosis, n (disease status
pretransplantation)
Non-Hodgkin lymphoma 18 (CR2, 2; CR3, 2; PR, 9; stable, 1;
refractory, 4)
Hodgkin lymphoma 5 (CR1, 1; PR, 2; refractory, 2)
Adult T cell leukemia/lymphoma 1 (CR1, 1)
AML 16 (CR1, 6; CR2, 5; CR3, 4; CR4, 1)
Acute lymphoblastic leukemia 5 (CR1, 1; CR2, 1; CR3, 3)
Chronic lymphocytic leukemia 6 (stable, 1; refractory, 5)
Multiple myeloma 7 (CR2, 1; PR, 3; stable, 2;
refractory, 1)
MDS/AML 1 (CR1, 1)
HLA mismatch, n, total (related
donor)
Both HVG and GVHD vectors 51 (4)
GVHD vector 8 (1)
One HLA antigen alone 48 (5)
HLA-A/-B/-C 20 (5)/5/23
One HLA antigen + 1 allele 10 (0)
HLA-A/-B/-C (additional allele
mismatch)
2/4/4
Two allele-level 1
HCT indicates hematopoietic stem transplantation; G-CSF, granulocyte
colony-stimulating factor; MDS, myelodysplastic syndrome; AML, acute
myelogenous leukemia; HVG, host-versus-graft; GVHD, graft-versus-
host disease.
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specific comorbidity index (HSCT-CI) [19] score
was available in 57 of the 59 patients; 12 patients had
an HSCT-CI score of 0, 21 patients had a score of 1
or 2, and 24 patients had a score of 3 or higher.
HLATyping and Matching
Final selection of unrelated donors was based on
the results of high-resolution HLA typing for HLA-
A, -B, -C, -DRB1, and -DQB1 alleles (Table 1). Seven
unrelated pairs and 1 related pair were mismatched
only in the GVHD vector and were not considered
evaluable for the rejection endpoint. Fifty-four unre-
lated pairs were mismatched for at least 1 antigen (19
at HLA-A, 8 at HLA-B, and 26 at HLA-C), except 1
patient, who had 2 allele mismatches (HLA-A and
HLA-B). All 5 related pairs were mismatched for 1
HLA-A antigen. Ten patients had, in addition to the
class I antigen mismatch, 1 allelic mismatch (2 at
HLA-A, 4 at HLA-B, and 4 at HLA-C).
Conditioning Regimen and GVHD Prophylaxis
Patients received Flu (30 mg/m2/day) on days 24,
23, and22 beforeHCT and 2GyTBI at a rate of 0.07Gy/minute from a linear accelerator on day 0. Post-
grafting immunosuppression with oral CsAwas started
at 5 mg/kg twice a day on day23 and continued to day
1180, then tapered to day 1365. MMF was given
orally at a dose of 15 mg/kg, based on adjusted body
weight (rounded to the nearest 250-mg increment),
every 8 hours from the evening of day 0 (4-6 hours after
HSCT infusion) up to day 1100, and then tapered at
a rate of approximately 11% per week for the next
8 weeks. The taper was completed by day1156 unless
GVHD occurred. When significant nausea or vomit-
ing occurred during MMF treatment, MMF was
administrated i.v. at the same dose. CsA levels were
measured by immunoassay, and doses were targeted
to achieve trough levels of 500 ng/mL for the first
28 days and 150-450 ng/mL thereafter. CsA was given
i.v. in patients not able to take it orally.
Escalation of Alemtuzumab Dose
The initial study design incorporated a provision
for the addition of low-dose alemtuzumab if more
than 1 rejection was seen in either of the first 2 cohorts
of 7 evaluable patients treated without alemtuzumab.
Eleven patients were enrolled in the first cohort, of
whom 7 were evaluable for the chimerism endpoint
and engrafted. In the second cohort, only 1 of 7 pa-
tients rejected the graft. Therefore, the protocol was
amended to allow continued accrual without alemtu-
zumab. A total of 59 patients underwent transplanta-
tion without alemtuzumab.
Collection of Hematopoietic Cells
All patients received G-CSF-mobilized PBSC
grafts. All related donors received 16 mg/kg/day of
G-CSF by s.c. injection for 5 consecutive days before
PBSC collection on days 21 and 0. Collection of
unrelated donor PBSCs was arranged through the
National Marrow Donor Program (NMDP) or
international donor centers. G-CSF 10 mg/kg was
administered by s.c. injection starting 5 days before
day 0 according to the NMDP protocol.
Supportive Care
All patients received standard prophylactic anti-
biotics with a third-generation cephalosporin or
quinolone when absolute neutrophil counts (ANCs)
declined to\500 mL. All patients received fluconazole
(400 mg/day) from the start of conditioning to at least
day 175 as prophylaxis for yeast infection. Trimetho-
prim-sulfamethoxazole (TMP-SMZ) was used as first-
line prophylaxis against Pneumocystis jiroveci, with
dapsone (50 mg twice a day) as second-line prophylaxis
until day 1180 or until discontinuation of immuno-
suppressive therapy. The varicella zoster virus (VZV)
prophylaxis (acyclovir 250 mg/m2 i.v., followed by
800 mg orally or valacyclovir 500 mg orally twice
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after discontinuation of all immunosuppressive ther-
apy. Preemptive treatment with ganciclovir was started
during the first 100 days after HSCTwhen cytomgalo-
virus (CMV) polymerase chain reaction or pp65 anti-
genemia for weekly CMV surveillance was positive.
After day 1100, surveillance and preemptive therapy,
on a weekly or biweekly basis, were recommended
for patients at intermediate or high risk for CMV
GVHD Grading and Treatment
Diagnosis and clinical grading of aGVHD and
cGVHD were done by local investigators according
to established criteria [20,21]. In most cases, biopsy
analysis confirmed the clinical diagnosis. Treatment
of aGVHD typically involved prednisone 1-2 mg/kg/
day and reinitiation of CsA at full dose if it had been
previously tapered or discontinued. Primary treatment
of extensive cGVHD comprised of prednisone 1 mg/
kg/day and CsA 5.0 mg/kg orally twice a day.
Treatment of Persistent/Progressive or
Relapsed Malignancies
Substantial persistent disease at day184 or disease
progression at any time was considered an indica-
tion for therapeutic intervention. In the absence of
GVHD, MMF was stopped and CsA was tapered
over 2 weeks orso, at the attending physician’s discre-
tion. If stopping immunosuppression provoked no
response, then chemotherapy or radiation therapy
was considered. Donor lymphocyte infusion (DLI)
was not offered on this trial.
Chimerism Analyses
Chimerism analysis of peripheral blood T cell
(CD31), granulocyte (CD331), and whole marrow
were performed on days 128, 156 184, 1 180, and
1365, and then yearly as described previously [7].
For the purposes of this study, full donor T cell chime-
rism was defined as . 95% donor CD31 T cells, and
graft rejection was defined as the inability to detect at
least 5% donor CD31 T cells (as a proportion of the
total T cell population in the PB) after HSCT. Mixed
or full donor chimerism was considered evidence of
donor engraftment. Sustained engraftment was de-
fined as continued evidence of donor engraftment up
to evaluation on day 184 without subsequent loss at
later evaluations.
Immune Reconstitution
Immune reconstitution was studied in 9 recipients
of HLA-class I mismatched unrelated grafts at
FHCRC. PB samples were obtained before condition-
ing, immediately before HSCT on day 0, and at 1, 3, 6,
and 12 months after HSCT. Mononuclear cells
(MNCs) were separated from blood specimens, stainedwith fluorochrome-conjugated mAbs, and analyzed by
3-color flow cytometry as described previously [22,23].
Naive B cells were represented by IgD1 B cells,
because most of these cells lack somatic mutations
[24-26]. Naive CD41 T cells were defined as
CD45RAhigh CD41 T cells, because this subset con-
tains thymic emigrants [27-29]. Naive CD81 T cells
were defined as CD11alow CD81 T cells, because vir-
tually all cord blood (CB) CD81T cells are CD11alow
and become CD11ahigh after activation [30,31].
CD281 T cells represent cells that can receive both
the T cell receptor-mediated signal and the CD28-
mediated costimulatory signal. Monocytes were
defined as CD141 MNCs. Natural killer (NK) cells
were defined as MNCs expressing CD16 or CD56
and not expressing CD3 or CD14. Dendritic cells
(DCs) were defined as HLA-DRhigh MNCs not ex-
pressing CD3, CD14, CD16, CD20, CD34, or CD56.
Statistical Analysis
Survival curves were estimated by the Kaplan-Me-
ier method. Cumulative incidence curves for aGVHD
and cGVHD and relapse treated death as a competing
risk. Cumulative incidence curves for nonrelapse mor-
tality (NRM) treated relapse as a competing risk.
Comparative analyses of mortality and competing
risk endpoints were performed via Cox regression; all
P values reflect likelihood ratio statistics from these
models and are 2-sided.RESULTS
Engraftment, Chimerism, and Graft Rejection
The median numbers of CD341 and CD31 cells
in the grafts were 7.0106 (range, 2.1-37.7 106) and
2.6108 (range, 0.3-6.6 108) cells/kg recipient body
weight, respectively. The median neutrophil nadir was
100 cells/mL (range, 0-860 cells/mL). The median du-
ration of neutropenia (ANC\0.5103/mL) was 9 days
(range, 0-33 days), and 9% of patients did not experi-
ence neutropenia. The median platelet nadir was
23 103/mL (range, 4-110 103/mL). The median du-
ration of thrombocytopenia (platelet count\20103/
mL) was 0 days (range, 0-23 days), and 62% of patients
did not develop thrombocytopenia.
The rates of full donorTcell chimerism in the evalu-
able patientswere76%atday128, 84%atday156, and
81%atday184. Sixteenpatientswere excluded for eval-
uation of the graft rejection outcome: 4 died early (less
than 30 days after HSCT), 8 received transplants from
donors mismatched only in the GVHD vector, and 4
received planned tandem auto-allo transplants. Four
patients died, at days18,116,123, and129, because
of NRM in 2 patients and disease progression in 2
patients. The patient who died at day 8 after HSCT
did not exhibit hematopoietic recovery.
Figure 1. Cumulative incidences of grade II, III, and IV aGVHD (A) and
clinical, extensive cGVHD (B).
Table 2. Incidence of Grade III and IV Toxicities (n 5 59)
Number of Episodes/Number of Patients (% of Patients)
Grade III Grade IV
Cardiovascular 16/16 (27) 11/7 (12)
Pulmonary 12/10 (17) 9/8 (14)
Hepatic 10/10 (17) 5/5 (8)
Renal/genitourinary 6/6 (10) 3/2 (3)
Gastrointestinal 2/2 (3) 7/7 (12)
Neurologic 2/2 (3) 2/2 (3)
Hemorrhage 3/3 (5) 0/0 (0)
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engraftment outcome, 77% achieved full donor T
cell chimerism at day 128, and 92% did so at day
156. Sustained engraftment was observed in 95% of
the evaluable patients.
Two patients (one with follicular lymphoma and
the other with AML) experienced early graft rejection
(on day 156 and day 184, respectively), and no late
graft rejections occurred. Both patients with early graft
rejection underwent successful retransplantation, one
from the same donor with conditioning consisting of
Flu and 4 Gy TBI, and the other from an alternative
HLA class I-mismatched donor with Flu, 4 Gy TBI,
and alemtuzumab (total dose, 10 mg).
GVHD
Forty-four of 57 patients (70%; excluding the 2 pa-
tients who experienced rejection) developed aGVHD
(grade I, n5 3; grade II, n5 25; grade III, n5 8; grade
IV, n 5 8). The cumulative incidences of grade II-IV
and grade III-IV aGVHDwere 69% and 26%, respec-
tively (Figure 1A). Twenty-one patients developed
cGVHD; the 3-year cumulative incidence of extensive
cGVHD was 41% (Figure 1B).
Toxicity and NRM
Thirty-five patients (59%) experienced at least one
nonhematopoietic grade III toxicity, and 20 (34%) had
at least one nonhematopoietic grade IV toxicity. The
most common grade III and IV nonhematopoietic
toxicities were cardiovascular and pulmonary compli-
cations (Table 2). Grade IV cardiac toxicities included
atrial fibrillation/flutter (n 5 3), elevated cardiac
enzymes suggestive of ischemic events (n5 3), pulmo-
nary embolism (n5 1), septic shock with kidney failure
requiring dialysis (n 5 1), acute myocardial infarction
(n 5 1), severe congestive heart failure (n 5 1), and
acute vascular leak syndrome (n 5 1). Grade IV pul-
monary toxicities included hypoxia/apnea requiring
intubation or pressure support (n5 7) and acute respi-
ratory distress syndrome (ARDS) (n 5 2). Grade IV
gastrointestinal toxicity consisted of diarrhea or colitis
associated with GVHD (n5 6) and small bowel perfo-
ration of unknown etiology (n 5 1).
Infection rates were calculated based on infections
within the first 100 days posttransplantation or until
death before day1100. The rates of documented viral
(including CMV reactivation), fungal, and bacterial
infection were 1.5, 0.3, and 2.1 per 100 patient-days,
respectively, with an overall infection rate of 3.9 per
100 patient-days.
Overall, 26 of 59 patients died from nonrelapse
causes. The cumulative probabilities of NRM were
22% at day 100, 36% at 1 year, and 47% at 2 years
(Figure 2A). The cumulative incidence of NRM at
2 years was 55% for patients in CR and 37% for thosenot in CR at the time of transplantation. The cumula-
tive incidence of NRM for the patients with AML and
MDS/AML was 56% at 2 years. Twenty patients died
of nonrelapse causes within 1 year after HSCT. Causes
of NRMwithin 1 year after HSCT included infections
associatedwithGVHD (n5 6),multiorgan failure (n5
3), infections without GVHD (n5 2), GVHD (n5 2),
secondary AML (n 5 1), ARDS (n 5 1), bronchiolitis
obliterans (n5 1), diffuse alveolar damage (n5 1),myo-
cardial infarction (n5 1), leukoencephalopathy (n5 1),
and congestive heart failure (n 5 1). Six patients died
of NRM more than 1 year after HCT. Causes of late
NRM included infections associated with GVHD
(n 5 2), infections without GVHD (n 5 2), cardiac
and respiratory failure (n 5 1), and bronchiolitis
Figure 2. Kaplan-Meier product estimates of NRM and relapse (A),
overall survival and progression-free survival (B), and overall survival
as stratified by HCT-CI score (C).
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cases, cGVHD contributed to the late death.
Relapse and Progression-Free Survival
The cumulative probability of relapse/progression
was 26% at 2 years (Figure 2A). Progression-free
survival (PFS) was 28% at 2 years (Figure 2B). The cu-
mulative incidence of relapse/progression at 2 years
was 14% for patients in CR and 38% for patients not
in CR at the time of HSCT. The cumulative incidence
of relapse for the patients with AML and MDS/AML(all of whom underwent transplantaion while in CR)
was 18% at 2 years. The 2-year probability of PFS
was 26% in high-risk disease and 28% in standard/
low-risk disease (P 5 .54).
Survival
Nineteen of 59 patients were alive a median of 24
months (range, 2-79 months) after HSCT. Of these
19, 14 were in CR, 2 were in PR, 2 had SD, and 1
had relapsed. The 2-year overall survival (OS) was
29% (Figure 2B). Grade III-IV aGVHD adversely
affected OS as a time-dependent covariate in a Cox
regression model (hazard ratio 5 8.35; 95% confi-
dence interval 5 3.4-21; P\ .0001).
The 2-year Kaplan-Meier probability of OS was
26% in patients receiving a graft from one HLA class
I antigen-mismatched donor (n 5 48) and 42% in
those with donors mismatched for 2 loci (n 5 11)
(P 5 .35). The 2-year probability of OS was 33% in
high-risk disease and 28% in standard/low-risk disease
(P 5 .92). Additionally, 2-year OS was 46% in the
patients with an HCT-CI score of 0, 26% in those
with a score of 1 or 2, and 20% in those with a score
of 3 or higher (P 5 .46) (Figure 2C).
Immune Reconstitution
Counts of innate immune cells (ie, NK cells, neu-
trophils, and monocytes) recovered within 1 month
posttransplantation (Figure 3A; data on neutrophils
and monocytes not shown). Recovery of dendritic cells
(DCs) was slower than that of NK cells, neutrophils,
and monocytes, and more so for the plasmacytoid sub-
set than for the conventional (‘‘myeloid’’) subset. T
cells recovered slowly over several months. B cell
counts were typically still low at 12 months; this was
true for both naive (surface IgD1) and memory (sur-
face IgD-) B cells (data not shown). CD81 T cell
counts reached the normal range between 6 and 12
months, whereas CD41 T cell counts were still low
at 12 months. Both naive and memory/effector T cells
recovered slowly (Figure 3B). CD28- T cells recovered
faster than CD281 T cells (Figure 3B).DISCUSSION
Studies of patients receiving MA conditioning and
unrelated marrow grafts have shown a higher rate of
graft rejection in patients given grafts mismatched
for 1 or more class I HLA antigens [5]. We sought to
determine whether graft rejection was increased
when HLA class I-mismatched grafts were trans-
planted after NMA conditioning, and found sustained
donor engraftment in 95% of recipients. Although this
trial was initially designed as a dose-escalation trial of
alemtuzumab according to the number of patients ex-
periencing graft rejection, the dose-escalation rule was
Figure 3. Recovery of lymphocyte subsets. Recovery of NK, B cells, dendritic cell precursors, CD41 and CD81 T cells after transplantation (A).
Recovery of naive, memory/effector, CD281 or CD282, CD41 and CD81 T cells after transplantation (B). The y-axis shows the number of cells
per microliter of blood. Patient medians (diamonds) and 25th-75th percentiles (error bars) are displayed. Normal medians (of 104 normal adults)
are indicated by the dashed horizontal lines; the thick horizontal lines denote the normal 10th-90th percentiles. Pretransplantation studies are arbitrarily
shown as performed using blood collected at 1-month pretransplantation, despite the fact that blood was drawn at any time between 1 month pretrans-
plantation and the morning of starting conditioning. Day 0 studies were performed using blood drawn immediately before graft infusion. Nine patient
blood samples were analyzed before transplantation, 7 were analyzed on day 0, 6 were analyzed at 1 month posttransplantation, 8 were analyzed at 3
months posttransplantation, 6 were analyzed at 6 months posttransplantation, and 5 were analyzed at 12 months posttransplantation.
390 Biol Blood Marrow Transplant 16:384-394, 2010H. Nakamae et al.never activated. Thus the combination of Flu and 2Gy
TBI, followed by a posttransplantation combination of
MMF given 3 times a day and CsA, was sufficient to
ensure a high rate of sustained full donorT-cell chime-
rism and engraftment even with HLA class I-
mismatched grafts.
We previously used MMF 15 mg/kg twice a day
administered from day 0 to day140, followed by taper
through day196, in combination with CsA as GVHDprophylaxis after NMA HLA-MUD HSCT. A high
graft rejection rate of 21% was found, however. By in-
creasing the MMF dose to 15 mg/kg 3 times a day (be-
cause of the short half-life [only 3 hours] of the active
metabolite of MMF) [7] and using only G-CSF mobi-
lized PBSCs as the stem cell source, we successfully re-
duced the rejection rate to 5% in NMA HSCT from
HLA-MUD [32]. Thus, in the current study we used
MMF 15 mg/kg 3 times a day and extended the
Figure 3. (Continued)
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the HLA-mismatched setting.We found sustained en-
graftment in 95% of the evaluable patients without the
use of alemtuzumab.
We detected no enhanced graft-versus-tumor ef-
fects with the use of HLA-mismatched unrelated
grafts. Observed cumulative probabilities of relapse/
progression of 22% at 1 year and 36% at 2 years
were very similar to those in our earlier HLA-matched
unrelated HSCT study (26% at 1 year and 31% at 2
years) [32]. When limited to patients not in CR at
HSCT, the CR rate in the present study was lower
than that in our previous study (27% vs 48%).
An association between HLA class I mismatches
and a high incidence of GVHD has been reported inrecipients of MA conditioning regimens followed by
unrelated donor HSCT [33-35]. Previous studies re-
ported that the cumulative incidence of grade II-IV
aGVHD varied from 43% to 74% after MA HSCT
with HLA-matched unrelated marrow and from 63%
to 80% after MA HSCT with 1 HLA antigen-mis-
matched unrelated marrow [36-39]. cGVHD was ob-
served in . 55% of patients after MA HSCT with
HLA-matched unrelated marrow and in 70% of pa-
tients after MA HSCT with 1 HLA antigen-mis-
matched unrelated marrow [21,36-39]. In a previous
study using the same NMA conditioning regimen (ie,
Flu and 2 Gy TBI), 103 patients received either 10/
10 HLA-matched (n 5 93) or single HLA class I al-
lele-level-mismatched (single each; n 5 10) unrelated
392 Biol Blood Marrow Transplant 16:384-394, 2010H. Nakamae et al.donor HSCT. In that study, we reported a cumulative
incidence of grade II-IV aGVHD and extensive
cGVHD of 53% and 56%, respectively [32]. Interest-
ingly, the 41% incidence of extensive cGVHD found
in the current study is comparable to or lower than
that observed in the HLA-matched unrelated setting.
The prolonged CsA and MMF administration in this
study may have contributed to the similar incidence
of cGVHD. On the other hand, the observed 69% in-
cidence of grade II-IV aGVHD in this study is higher
than that seen in the HLA-matched unrelated setting
[32]. The 47% cumulative probability of NRM at 2
years in the current study is also higher than that
seen in the HLA-matched unrelated setting. In addi-
tion, in the current study, aGVHD contributed to
death in 9 of 26 nonrelapse deaths (35%), and 6 of 7
(86%) grade IV gastrointestinal episodes were associ-
ated with gut GVHD that directly or indirectly caused
mortality.
As might be expected, there was a concern that the
prolonged CsA and MMF administration in the pres-
ent protocol might have increased the risk of infection.
Indeed, the incidence of infection was higher than that
in our earlier study on unrelated HSCT (documented
rates of viral, fungal, and bacterial infection of 0.86,
0.26, and 1.05 per 100 patient-days, respectively
[32]). In 12 of 26 patients (46%), NRM was associated
with infection.
Because excessive immunosuppression can lead to
high rates of relapse and infection due to delayed im-
mune reconstitution, an optimal prophylactic regimen
for GVHD in HLA-mismatched or unrelated HSCT
has been explored by other investigators. Alemtuzu-
mab (total 20-100 mg/person, or 1.2 mg/kg) has
been applied in HLA-haploidentical related and
HLA-matched and -mismatched unrelated HSCT
[40-43]. Some investigators have reported that alemtu-
zumab-containing regimens were highly effective in
preventing both cGVHD and aGVHD without in-
creased risk of relapse [40,41]; however, high relapse
rates, particularly in patients with active disease at
HSCT (5 of 8 patients [63%]) [42], and high infection
rates (serious infections complication 62.2%) [43]
because of delayed immune reconstitution also have
been reported. Furthermore, in a recent publication,
we reported that HLA-haploidentical NMA related
HSCT with high-dose posttransplantation cyclophos-
phamide showed an acceptable sustained engraftment
rate of . 95% and improved control of aGVHD
(34% for grade II-IV and 6% for grade III-IV) with
no increased risk of severe infection, but with a rela-
tively high relapse rate of 51% at 1 year [44]. In our
earlier retrospective study, extensive cGVHD, but
not grade II-IV aGVHD, was significantly associated
with decreased risk of relapse or progression without
increased NRM [45]. These data indicate that intensi-
fied prophylaxis for aGVHD, but not cGVHD, withan additional immunosuppressive agent, such as low-
dose alemtuzumab [46] or sirolimus [47], may be a rea-
sonable strategy to improve outcome.
The observed OS in all 3 groups stratified by
HSCT-CI score was inferior to that in recipients of
HLA-matched related and/or unrelatedHSCT.These
data suggest that HLA-class I disparity might be an-
other independent outcome factor in the nonmyeloa-
blative setting.
Immune reconstitution was similar to that after
HLA-matched unrelated donor NMA HSCT [48],
with the exception of slower recovery of CD81T cells
and B cells. Both naive and memory/effector CD81T
cells recovered slowly, suggesting reduced thymopoie-
sis and peripheral expansion, possibly because many of
our patients had GVHD (clinical or subclinical) and
were treated with prolonged immunosuppressive ther-
apy. The slow recovery of B cells also may result from
the fact that many patients had GVHD, because
GVHD and/or its treatment hamper B lymphopoiesis
[49,50]. The slow recovery of CD81 T cells and B
cells might have contributed to the relatively high in-
fection rates detected.
In conclusion, this study demonstrates the feasibil-
ity of NMAHSCT fromHLA class I-mismatched do-
nors using Flu and low-dose TBI conditioning.
Although almost 30% of the patients achieved long-
term survival with this approach, there was a high
incidence of aGVHD, and NRM decreased survival
compared with that in fully HLA-matched unrelated
patients. Future studies of more intense early prophy-
laxis of GVHD in this HLA class I-mismatched setting
may decrease severe aGVHD and improve survival.ACKNOWLEDGMENTS
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